JP2009516697A - 癌および炎症性疾患の治療のためのikk−ベータ阻害剤としての[4−(ベンゾ[b]チオフェン−2−イル)ピリミジン−2イル]アミン誘導体 - Google Patents

癌および炎症性疾患の治療のためのikk−ベータ阻害剤としての[4−(ベンゾ[b]チオフェン−2−イル)ピリミジン−2イル]アミン誘導体 Download PDF

Info

Publication number
JP2009516697A
JP2009516697A JP2008541463A JP2008541463A JP2009516697A JP 2009516697 A JP2009516697 A JP 2009516697A JP 2008541463 A JP2008541463 A JP 2008541463A JP 2008541463 A JP2008541463 A JP 2008541463A JP 2009516697 A JP2009516697 A JP 2009516697A
Authority
JP
Japan
Prior art keywords
group
benzo
carboxylic acid
mmol
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2008541463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009516697A5 (https=
Inventor
カール・ロバート・ダーンク
ホ−シェン・リン
チュアン・シー
キュー・メイ・ワン
チャン・ボ
マイケル・エンリコ・リチェット
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2009516697A publication Critical patent/JP2009516697A/ja
Publication of JP2009516697A5 publication Critical patent/JP2009516697A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2008541463A 2005-11-18 2006-11-15 癌および炎症性疾患の治療のためのikk−ベータ阻害剤としての[4−(ベンゾ[b]チオフェン−2−イル)ピリミジン−2イル]アミン誘導体 Ceased JP2009516697A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73809705P 2005-11-18 2005-11-18
PCT/US2006/060911 WO2007092095A2 (en) 2005-11-18 2006-11-15 [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.

Publications (2)

Publication Number Publication Date
JP2009516697A true JP2009516697A (ja) 2009-04-23
JP2009516697A5 JP2009516697A5 (https=) 2009-12-17

Family

ID=38345605

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008541463A Ceased JP2009516697A (ja) 2005-11-18 2006-11-15 癌および炎症性疾患の治療のためのikk−ベータ阻害剤としての[4−(ベンゾ[b]チオフェン−2−イル)ピリミジン−2イル]アミン誘導体

Country Status (27)

Country Link
US (1) US7547691B2 (https=)
EP (1) EP1989200B1 (https=)
JP (1) JP2009516697A (https=)
KR (1) KR100990771B1 (https=)
CN (1) CN101309918B (https=)
AR (1) AR057911A1 (https=)
AT (1) ATE437873T1 (https=)
AU (1) AU2006337626B2 (https=)
BR (1) BRPI0618245A2 (https=)
CA (1) CA2629336A1 (https=)
CR (1) CR9947A (https=)
DE (1) DE602006008187D1 (https=)
DK (1) DK1989200T3 (https=)
EA (1) EA014426B1 (https=)
EC (1) ECSP088456A (https=)
ES (1) ES2329085T3 (https=)
IL (1) IL190489A0 (https=)
MA (1) MA30053B1 (https=)
NO (1) NO20082594L (https=)
PE (1) PE20070833A1 (https=)
PL (1) PL1989200T3 (https=)
PT (1) PT1989200E (https=)
SI (1) SI1989200T1 (https=)
TN (1) TNSN08227A1 (https=)
TW (1) TW200800201A (https=)
WO (1) WO2007092095A2 (https=)
ZA (1) ZA200803940B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2007752T3 (pl) 2006-03-31 2011-02-28 Janssen Pharmaceutica Nv Benzoimidazol-2-ilopirymidyny i pirazyny jako modulatory receptora histaminowego H4
AU2007275221A1 (en) * 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
DK2125794T3 (da) * 2006-12-21 2011-01-24 Lilly Co Eli Imidazolidinonylaminopyrimidin-forbindelser til behandling af cancer
ES2349169T3 (es) * 2006-12-21 2010-12-28 ELI LILLY & COMPANY Compuestos de imidazolidinonil aminopirimidina para el tratamiento del cáncer.
CN101679396B (zh) 2007-05-16 2012-06-06 伊莱利利公司 三唑基氨基嘧啶化合物
US8063035B2 (en) 2007-05-16 2011-11-22 Eli Lilly And Company Triazolyl aminopyrimidine compounds
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
TWI498326B (zh) 2008-06-30 2015-09-01 Janssen Pharmaceutica Nv 用於製備經取代之嘧啶衍生物之化合物
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
MX2012001974A (es) 2009-08-19 2012-04-11 Ambit Biosciences Corp Compuestos de biarilo y metodos de uso de los mismos.
CN102858764B (zh) 2010-04-27 2014-08-20 和记黄埔医药(上海)有限公司 嘧啶基吲哚化合物
WO2013058824A1 (en) 2011-04-07 2013-04-25 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
US9245773B2 (en) 2011-09-02 2016-01-26 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor device packaging methods and structures thereof
CN103159742B (zh) * 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
WO2013119895A1 (en) * 2012-02-08 2013-08-15 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
CN105085434B (zh) * 2014-05-09 2018-02-09 上海特化医药科技有限公司 硫乙拉嗪或其中间体的制备方法
WO2017076888A1 (en) * 2015-11-03 2017-05-11 Janssen Pharmaceutica Nv 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
PT3494119T (pt) 2016-07-29 2024-12-10 Pgi Drug Discovery Llc Compostos e composições e seus usos
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
WO2018140599A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
CA3070993C (en) 2017-08-02 2025-05-20 Sunovion Pharmaceuticals Inc. ISOCHROMANE COMPOUNDS AND THEIR USES
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
EP3938045A1 (en) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011279A1 (en) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
WO2004089913A1 (en) * 2003-04-11 2004-10-21 Novartis Ag Aminopyrimidine derivatives and their medical use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831207B1 (en) 2004-12-17 2012-11-14 Amgen Inc. Aminopyrimidine compounds as plk inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011279A1 (en) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
WO2004089913A1 (en) * 2003-04-11 2004-10-21 Novartis Ag Aminopyrimidine derivatives and their medical use

Also Published As

Publication number Publication date
AU2006337626A8 (en) 2008-06-19
ECSP088456A (es) 2008-06-30
DE602006008187D1 (de) 2009-09-10
KR100990771B1 (ko) 2010-10-29
US20080306082A1 (en) 2008-12-11
WO2007092095A3 (en) 2007-11-08
TNSN08227A1 (en) 2009-10-30
CR9947A (es) 2008-11-28
WO2007092095A2 (en) 2007-08-16
CN101309918A (zh) 2008-11-19
KR20080059451A (ko) 2008-06-27
BRPI0618245A2 (pt) 2011-08-23
IL190489A0 (en) 2008-11-03
EA014426B1 (ru) 2010-12-30
US7547691B2 (en) 2009-06-16
TW200800201A (en) 2008-01-01
NO20082594L (no) 2008-06-10
AR057911A1 (es) 2007-12-26
ES2329085T3 (es) 2009-11-20
PL1989200T3 (pl) 2009-12-31
PT1989200E (pt) 2009-10-12
AU2006337626A1 (en) 2007-08-16
CA2629336A1 (en) 2007-08-16
AU2006337626B2 (en) 2012-03-22
CN101309918B (zh) 2010-12-29
PE20070833A1 (es) 2007-08-27
EP1989200B1 (en) 2009-07-29
EA200801362A1 (ru) 2009-02-27
ATE437873T1 (de) 2009-08-15
ZA200803940B (en) 2009-09-30
SI1989200T1 (sl) 2009-12-31
EP1989200A2 (en) 2008-11-12
DK1989200T3 (da) 2009-11-09
MA30053B1 (fr) 2008-12-01

Similar Documents

Publication Publication Date Title
KR100990771B1 (ko) 암 및 염증성 질환 치료를 위한 ikk-베타 억제제로서의[4-벤조[b]티오펜-2-일)피리미딘-2-일]-아민 유도체
EP2044051B1 (en) Pyridine and pyrazine derivatives as mnk kinase inhibitors
AU2004228352B2 (en) Aminopyrimidine derivatives and their medical use
US20090233928A1 (en) Imidazolo-5-yl-2-anilo-pyrimidines as agents for the inhibition of cell proliferation
KR20080110998A (ko) Jak­2 조절자로서 4­아릴­2­아미노­피리미딘 또는 4­아릴­2­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
AU2007242594A1 (en) Pyrimidine derivatives as PI3K inhibitors
CN102892761A (zh) 4-氨基嘧啶衍生物和它们作为腺苷a2a 受体拮抗剂
WO2002051806A1 (en) Carbazole derivatives and their use as neuropeptide y5 receptor ligands
KR20140103996A (ko) Lrrk2 조절제로서 아미노피리미딘 유도체
CA2632881A1 (en) Sulfoximine-substituted pyrimidines, their preparation and use as drugs
NZ564872A (en) Novel 2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
CN101511824A (zh) 用于治疗糖原合酶激酶(gsk3)相关疾病的咪唑-嘧啶衍生物
JP2009537485A (ja) 細胞周期キナーゼの阻害剤としての2,4−ジアミノピリミジン
CN101273047A (zh) 作为蛋白激酶抑制剂的噻吩并[2,3-b]吡啶-5-甲腈
KR101730205B1 (ko) 신규 (헤테로사이클/테트라히드로피리딘)-(피페라지닐)-1-알카논 및 (헤테로사이클/디히드로피롤리딘)-(피페라지닐)-1-알카논유도체, 및 p75 억제제로서의 그의 용도
AU2008254318A1 (en) Triazolyl aminopyrimidine compounds
CN101479277A (zh) 作为pi3k抑制剂的嘧啶衍生物
AU2002217269A1 (en) Carbazole derivatives and their use as neuropeptide Y5 receptor ligands

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091028

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120703

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20121127